Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Bench-Top Stability Evaluation – V 2.0

Posted on By

BA-BE Studies: SOP for Bench-Top Stability Evaluation – V 2.0

Standard Operating Procedure for Bench-Top Stability Evaluation of Analyte in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/177/2025
Supersedes SOP/BA-BE/177/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for evaluating bench-top stability of analytes in plasma under ambient temperature conditions during sample preparation and handling, in support of bioavailability/bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all bench-top stability evaluations carried out in the bioanalytical laboratory for plasma samples prepared for BA/BE studies and stored at ambient conditions prior to processing.

3.

Responsibilities
  • Analyst: Prepares, labels, exposes, and analyzes stability samples.
  • Supervisor: Reviews data and ensures compliance with method validation requirements.
  • QA: Ensures all documentation is accurate and conforms to regulatory standards.

4. Accountability

The Bioanalytical Laboratory Manager is accountable for ensuring that bench-top stability evaluations are properly planned, conducted, and documented in compliance with ICH M10 and US FDA guidelines.

5. Procedure

5.1 Sample Preparation

  1. Prepare at least six replicates of Low QC (LQC) and High QC (HQC) samples using validated bioanalytical methods.
  2. Label each tube with:
    • Sample ID
    • QC level
    • Date and time of preparation
    • Bench-top exposure start time
  3. Document details in Annexure-1: Bench-Top Stability Log.

5.2 Exposure Conditions

  1. Place labeled samples on the laboratory bench at ambient temperature (20–25°C).
  2. Expose samples for a pre-defined period (e.g., 4, 6, 8, 24 hours) as per method validation protocol.
  3. Do not allow exposure beyond validated time frame.
  4. Return exposed samples to freezer (-20°C or -70°C) until ready for analysis.

5.3 Sample Analysis

  1. Analyze the bench-top exposed samples with a fresh calibration curve and system suitability checks.
  2. Use validated LC-MS/MS method for quantification of analyte.
  3. Compare the measured concentrations to nominal concentrations of LQC and HQC.

5.4 Acceptance Criteria

  1. Mean measured concentration should be within ±15% of the nominal value.
  2. Coefficient of variation (%CV) should be ≤15%.
  3. Summarize results in Annexure-2: Bench-Top Stability Summary.

5.5 Documentation and Reporting

  1. Compile data, calculations, chromatograms, and system suitability results.
  2. Prepare a final report and submit to QA for review and archival.
  3. Incorporate approved summary in method validation report or study report.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LQC: Low Quality Control
  • HQC: High Quality Control
  • %CV: Percent Coefficient of Variation
  • QA: Quality Assurance

7. Documents

  1. Bench-Top Stability Log – Annexure-1
  2. Bench-Top Stability Summary – Annexure-2

8. References

  • ICH M10: Bioanalytical Method Validation
  • US FDA Guidance for Industry: Bioanalytical Method Validation (2022)
  • Internal Method Validation Protocol

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Bench-Top Stability Log

Sample ID QC Level Prep Date Start Time End Time Exposed By
BE177-BT-01 LQC 16/04/2025 09:00 15:00 Sunita Reddy

Annexure-2: Bench-Top Stability Summary

QC Level Nominal (ng/mL) Mean Measured %CV % Difference Status
LQC 20.0 19.3 4.9 -3.5% Accepted
HQC 1500.0 1512.4 2.6 +0.8% Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
17/04/2025 2.0 Updated exposure durations, added annexures ICH M10 Alignment QA Head
See also  BA-BE Studies: SOP for Establishing Quality Agreements with CROs - V 2.0
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Elixir Department: SOP for Sequential Batch Manufacturing – V 2.0
Next Post: Biosimilars: SOP for Inline Analytics (Raman, NIR) in Bioreactor Operations – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version